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Abstract. We have previously demonstrated the involvement of
milk fat globule-epidermal growth factor-factor 8 (MFG‑E8)
in reducing neutrophil infiltration in a murine model of acute
lung injury (ALI). In the present study, we aimed to delineate
the mechanisms through which MFG‑E8 attenuates neutrophil
migration. Recombinant human MFG‑E8 (rhMFG‑E8) was
expressed and purified in our facility. The human differentiated neutrophil cell line, dHL‑60, was treated with rhMFG‑E8
and cell migration assay was performed in a Boyden chamber
using recombinant interleukin‑8 (IL‑8) as the chemoattractant.
Surface CXCR2 and intracellular G protein‑coupled receptor
kinase 2 (GRK2) levels were evaluated by flow cytometry
or western blot analysis. The levels of mitogen‑activated
protein (MAP) kinases were determined by western blot
analysis. Treatment with rhMFG‑E8 resulted in a significant
inhibition of dHL‑60 cell migration in a dose‑dependent
manner. There was a 46% decrease in CXCR2 expression in
the rhMFG‑E8‑treated dHL‑60 cells, which was associated
with a 32% increase in GRK2 expression. In the dHL‑60 cells,
treatment with rhMFG‑E8 promoted the phosphorylation
of p38 and extracellular signal-regulated kinase (ERK)
within 10‑30 min. The use of SB203580, a p38 inhibitor, and
PD98059, an ERK inhibitor, resulted in the restoration of
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dHL‑60 cell migration which was significantly inhibited treatment with rhMFG‑E8. Furthermore, blocking the MFG‑E8
receptors, αvβ3/αvβ5‑integrins, by anti‑αv‑integrin neutralizing
antibody (Ab) inhibited the activation of p38 and ERK, and
reversed the rhMFG‑E8‑induced inhibition of dHL‑60 cell
migration. Finally, treatment of the dHL‑60 cells with
SB203580 and PD98059 neutralized the rhMFG‑E8‑induced
downregulation of CXCR2 expression and upregulation of
GRK2 expression, as well as the inhibitory effects on cell
migration. Our findings reveal a novel mechanism of action
of MFG‑E8 through which it inhibits neutrophil migration
through αvβ3-integrin-dependent MAP kinase activation.
Introduction
Neutrophils are the first cell type recruited to infected tissue;
they sterilize the wound, clearing out invading bacteria through
phagocytosis and subsequent killing by the release of reactive
oxygen species (ROS) (1,2). Activated neutrophils also secrete
numerous cytokines, chemokines, proteolytic enzymes stored
in preformed granules, and pro‑inflammatory products of
arachidonic acid (prostaglandin E2 and leukotrienes), which
collectively serve to recruit additional immune cells, remove
cell debris and fine‑tune the adaptive immune response (1,2).
Although these functions of neutrophils are crucial components
of normal wound healing, exaggerated or long‑term neutrophil
activity can contribute to tissue damage as a result of the uncontrolled release of ROS into the extracellular milieu (1,2). Under
normal conditions, resting neutrophils have a short half-life and
undergo apoptosis in the circulation after 6‑9 h (3). However,
when neutrophils reach a site of inflammation, apoptosis is
delayed by inflammatory cytokines present in the tissues, which
not only provide additional time for completion of their microbicidal function, but also exaggerate inflammation and tissue
injury (4). Thus, neutrophils function as a ‘double‑edged sword’.
In order to prevent these adverse effects due to the release of
proteolytic enzymes, such as elastase and myeloperoxidase and
ROS, neutrophils should either be removed quickly from the
inflamed tissue or their recruitment should be tightly controlled.
Neutrophil recruitment is critical to pulmonary inflammatory
responses associated with acute lung injury (ALI) (5,6). In our
previous studies utilizing animal models of sepsis, ALI, and
gut ishchemia‑reperfusion (I/R) we observed an enhanced
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neutrophil infiltration at multiple organs, particularly into the
lungs, liver and intestines, which led to the disruption of endothelial barrier function and promoted extravascular host tissue
damage during uncontrolled inflammation (7‑9). Conversely,
the use of therapeutic regimens that restrict tissue neutrophil
infiltration may help the host to overcome serious diseases in
which abnormal neutrophil infiltration is a major concern.
Neutrophil trafficking into pulmonary tissue and air spaces
in response to a gradient of chemoattractant is essential for
their localization at sites of infection and inflammation to
execute their functions (1). Neutrophil migration into the lungs
is mediated by a complex cascade of rolling, adhesion and transendothelial migration, involving a number of factors that have
already been well defined (10). Neutrophil infiltration into the
lungs is mediated by a local production of chemokines released
by macrophages, as well as other cell types in response to
inflammation (11,12). The levels of CXC chemokines, such as
interleukin‑8 (IL‑8) are significantly elevated in the bronchoalveolar lavage fluid (BALF) of patients with acute respiratory
distress syndrome (ARDS), and increased IL‑8 levels have
been shown to be associated with increased neutrophil infiltration (13,14). In rodents, the IL‑8 homologue, CINC‑1/2,
and MIP‑2 regulate neutrophil recruitment into the lungs
during experimental ALI through the chemokine receptor,
CXCR2 (15,16). CXCR2 is a member of the G protein‑coupled
receptor (GPCR) superfamily and is expressed in neutrophils,
monocytes and T cells (17). CXCR2 mediates neutrophil
chemotaxis in response to tissue injury and many types of
infections (17,18). G protein‑coupled receptor kinase 2 (GRK2)
has emerged as a key regulator of GPCR and other plasma
membrane receptors triggered by chemotactic messengers (19).
It has been demonstrated that the expression, localization and
function of CXCR2 in polymorphonuclear leukocytes (PMNs)
are tightly regulated by intracellular GRK2 (20‑22). Upon
activation, GRK2 phosphorylates CXCR2 and causes receptor
desensitization and internalization, leading to the downregulation of neutrophil chemotaxis (20‑22). Increasing evidence
points to the occurrence of complex mechanisms modulating
the subcellular localization, activity and expression levels of
GRK2, which reveals new functional interactions of this kinase
with various cellular proteins and transduction cascades (23).
It has also been reported that GRK2 co‑localizes with the
mitogen‑activated protein (MAP) kinases, and its activity and
bidirectional regulation are mediated through the MAP kinase
pathways (23‑25).
Milk fat globule‑epidermal growth factor-factor 8
(MFG‑E8) is a secretory glycoprotein with bivalent binding
activity to αvβ3‑integrin and acidic phospholipids, such as
phosphatidylserine (PS) capable of carrying out versatile
functions in cell physiology, such as the recognition of target
cells and membrane vesicles by phagocytes (26,27), the
development of male reproductive organs and cells (28), cell
reorganization in mammary gland development and involution (29,30), and the regulation of inflammatory responses,
such as macrophage activation (31,32) and neutrophil infiltration (8). It was named after its origin and structural properties,
i.e., its origin in milk fat globule and its sequence homology
to epidermal growth factor (EGF)‑like domains of Drosophila
Notch protein and C‑terminal domains of human coagulation
factors Ⅷ and V (F5/8‑type C domain). In our previous
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studies, we observed a significant decrease in MFG‑E8 expression in the immune reactive organs following sepsis, ALI and
gut I/R injury, and exogenous treatment with recombinant
murine MFG‑E8 (rmMFG‑E8) markedly improved survival
by attenuating systemic inflammation and the infiltration of
neutrophils at vital organs (8,9,33). Therefore, in the present
study, we aimed to elucidate the pivotal mechanisms through
which MFG‑E8 regulates neutrophil migration in response to
the chemoattactant, IL‑8. Based on our hypothesis, we demonstrate that the treatment of the human neutrophil‑like cell line,
HL‑60, with recombinant human MFG‑E8 (rhMFG‑E8) results
in a decreased migration ability towards IL‑8. We further
clarified the pivotal role of MFG‑E8 in the αvβ3‑integrin mediated downregulation of neutrophil migration by modulating
the surface expression of CXCR2 through GRK2‑dependent
pathways. We also deduced a novel and previously unexplored mechanism involving the MAP kinase pathways in
the effects of MFG‑E8 on the inhibition of neutrophil migration. Importantly, the present findings identify an additional
role of MFG‑E8 in inhibiting neutrophil infiltration through
MAP kinase‑dependent pathways. Thus, this may prove to be
an effective therapeutic strategy in the treament of diseases in
which enhanced neutrophil infiltration is a major concern.
Materials and methods
HL‑60 cell culture and differentiation. HL‑60 human promyelocytic leukemia cells, obtained from the American Type
Culture Collection (ATCC; Manassas, VA, USA) were cultured
in a T‑25 cell culture flask at a density of 2x105 cells/ml in 15 ml
RPMI‑1640 medium supplemented with 10% fetal bovine
serum (FBS), and penicillin and streptomycin. The cells were
kept in 37˚C incubator under humidified conditions containing
5% CO2. The cells were grown to a density of 1x106 cells/ml,
at which time they were passaged by seeding into a new flask
at 2x105 cells/ml. In order to induce the differentiation of the
HL‑60 [differentiated HL‑60 (dHL‑60)] cells, 1x105 cells/ml at
the mid‑log growth phase were grown in a T‑25 flask in 15 ml
of RPMI‑1640 medium containing 190 µl of 100% dimethyl
sulfoxide (DMSO) supplemented with 10% FBS, and penicillin/streptomycin antibiotics for a period of 5‑7 days, as
previously described (34), which induced their differentiation
into PMNs.
Stimulation of dHL‑60 cells with rhMFG‑E8. The expression,
purification and functional characterization of rhMFG‑E8 were
performed according to a previously described protocol (35). In
brief, a 1,095 bp fragment encoding the mature region of human
MFG‑E8 was obtained by polymerase chain reaction amplification and cloned into the SalI and NotI site of the pET‑28a(+)
vector (Novagen, Inc., Madison, WI, USA) downstream of
the phage T7 RNA polymerase promoter. The plasmid was
transformed into E. coli BL21 (DE3) cells grown at 37˚C in
2YT medium (Invitrogen Life Technologies, Grand Island,
NY, USA) with kanamycin overnight. rhMFG‑E8 protein
production was induced by the addition of isopropyl‑β‑D‑thio
galactopyranoside (IPTG) to a final concentration of 1.0 mM and
cell growth continued for 5 h at 25˚C. The cells were harvested
by centrifugation at 6,000 rpm and the induced rhMFG‑E8
protein was purified according to the manufacturer's instruc
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tions (Novagen, Inc.). The rhMFG‑E8 fractions were pooled
and the endotoxin of the protein solution was removed by phase
separation using Triton X‑114. The content of lipopolysaccharide (LPS) in the sample was determined using the Limulus
Amebocyte Lysate assay kit (BioWhittaker, Walkersville, MD,
USA). The purity of rhMFG‑E8 was evaluated by SDS‑PAGE
on a 10‑20% Tris‑HCl gel and visualized using the GelCode
Blue Stain Reagent (Pierce Biotechnology, Inc., Rockford, IL,
USA). The final product was concentrated by Amicon ultra‑15
centrifugal filter devices to the designed concentration and
stored at ‑20˚C. For the stimulation of the dHL‑60 cells with
rhMFG‑E8, a total of 1.5x106 cells/ml was placed into 1.5 ml
microcentrifuge tubes in serum‑free Opti‑MEM (Invitrogen
Life Technologies) and then stimulated with rhMFG‑E8 at a
dose of 500 ng/ml for the indicated period of time. Subsequently,
experiments were carried out for the assessment of cell migration, and intracellular signal transduction by western blot
analysis and flow cytometry.
In vitro cell migration assay. The migration assays were
conducted in a modified 24‑well (3.0 µm) Boyden chamber
(BD Biosciences, San Jose, CA, USA). Following differentiation, the dHL‑60 cells (3x105) were pre‑treated with
either rhMFG‑E8 (125-1,000 ng/ml) or PBS for 2 h, and
then plated in the Boyden chamber inserts and medium with
50 ng/ml of recombinant human IL‑8 (rhIL-8; R&D Systems,
Minneapolis, MN, USA) was placed in the outer compartment
which served as a chemoattractant. After 1.5 h of incubation,
the upper surface of the filter was swabbed with cotton‑tipped
applicators to remove non‑migratory cells. The migrated cells
were fixed with 4% paraformaldehyde (PFA) and stained with
propidium iodide (PI) (1 µg/ml). A total of 6 random microscopic fields per well were counted.
Flow cytometric analysis. To examine the surface CXCR2
and intracellular GRK2 expression levels, the dHL‑60
cells (1.5x106 cells) treated with rhMFG‑E8 (500 ng/ml) for
2 h were first surface-stained with PE‑CXCR2 (BioLegend,
San Diego, CA, USA), and subsequently, to determine intracellular GRK2 expression, the cells were fixed and permeabilized
with IntraPrep (Beckman Coulter, Fullerton, CA, USA), followed
by staining with FITC‑GRK2 antibodies (Abcam, Cambridge,
MA, USA). After washing, the stained cells were analyzed
using a FACSVerse flow cytometer (BD Biosciences). Data were
analyzed by FlowJo software (FlowJo, LLC, Ashland, OR, USA)
with 15,000 events per sample. Isotype controls and Fc Receptor
Blocker (both from BioLegend) were used for all the samples.
Western blot analysis. The dHL‑60 cells (1.5x106/ml) were
placed into 1.5 ml microfuge tubes with Opti-MEM and then
stimulated with either rhMFG‑E8 (500 ng/ml) or PBS for
different periods of time. Following incubation, the cells were
centrifuged at 200 x g for 5 min and the supernatants were
removed. The cell pellet was then lysed by the addition of
80‑100 µl of loading buffer containing 0.5 M Tris‑HCl, pH 6.8,
16% glycerol, 10% SDS and 1% Bromophenol Blue. The lysate
was then heated to 95˚C for 5 min and an equal volume (20 µl)
of each lysate per lane was loaded onto a 4‑12% Bis‑Tris gel
(Invitrogen Life Technologies) and transferred onto a 0.2‑µm
nitrocellulose membrane (Invitrogen Life Technologies). The

membrane was incubated overnight at 4˚C with the primary
antibodies as obtained from respective vendors: rabbit
anti‑GRK2 monoclonal antibody (Cat. no. ab32558; Abcam),
rabbit anti‑phospho‑p38 (Cat. no. 9211), anti‑phospho‑extracellular signal-regulated kinase (ERK)1/2 (Cat. no. 9101),
and the total antibodies for p38 (Cat. no. 9212) and ERK1/2
(Cat. no. 4695), (all from Cell Signaling Technology, Danvers,
MA, USA), at a 1:1,000 dilution, reacted with peroxidase‑conjugated goat anti‑rabbit secondary antibody (Cat. no. 4030‑05;
SouthernBiotech, Birmingham, AL, USA) at a 1:10,000 dilution at room temperature for 2 h, and washed 5 times in TBST.
The immunoblot was washed, stripped off and reprobed with
mouse anti‑β‑actin antibody (Cat. no. A2228; Sigma‑Aldrich,
St. Louis, MO, USA) as a loading control. The resulting signals
were detected by ECL (GE Healthcare, Buckinghamshire,
UK), and the band intensities were assessed by densitometry
using ImageJ software, as previously described (36).
In vitro neutralization of αv‑integrin. For the in vitro neutralization of the αv‑integrin receptor, a total of 1.5x106 dHL‑60 cells
were placed into 1.5 ml microfuge tubes containing 1 ml of
Opti‑MEM. The cells were then pre‑treated with 1 µg/ml of
each of the IgG isotype control or anti‑αv‑integrin neutralizing
antibody (both from BioLegend) for 1 h at 37˚C. Subsequently,
the cells were stimulated with rhMFG‑E8 (500 ng/ml) or PBS
for different periods of time and then analyzed by flow cytometry or western blot analysis.
Inhibition of p38 and ERK using chemical inhibitors. The
dHL‑60 cells were placed into 1.5 ml microfuge tubes at a
density of 1.5x106 cells/ml in Opti‑MEM. The cells were then
pre‑treated with the p38 inhibitor, SB203580 and the ERK
inhibitor, PD98059 (both from Tocris Bioscience, Ellisville,
MO, USA), at a concentration of 10 µM for each for 1 h at 37˚C.
Following incubation, the cells were stimulated with rhMFG‑E8
or PBS for 2 h followed by the assessment of CXCR2 and GRK2
expression by flow cytometry and western blot analysis.
Statistical analysis. All data are expressed as the means ± SE
and compared by one‑way ANOVA and the Stud
ent‑Newman‑Keul (SNK) test. The Student's t‑test was used
when only 2 groups were compared. Differences in values were
considered significant if P<0.05.
Results
rhMFG‑E8 inhibits dHL‑60 cell migration in a dosedependent manner. To examine the effects of rhMFG‑E8
on neutrophil migration, the dHL‑60 cells were pre‑treated
with various concentrations of rhMFG‑E8 for 2 h. The cells
were then allowed to proceed for migration towards rhIL‑8
as a chemoattractant using a Boyden chamber. As shown
in Fig. 1A and B, pre‑treatment of the dHL‑60 cells with
rhMFG‑E8 led to a significantly decrease in their migration
towards rhIL‑8 in a dose‑dependent manner. Since the most
notable decrease in their migration occurred following stimulation with rhMFG‑E8 at the doses of 500 and 1,000 ng/ml,
among these 2 doses we decided to utilize the lesser dose of
500 ng/ml of rhMFG‑E8 protein for the subsequent in vitro
experiments.
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Figure 1. Recombinant human milk fat globule‑epidermal growth factor-factor 8 (rhMFG‑E8) attenuates HL‑60 cell migration. (A) Differentiated HL‑60
cells (3x105) were pre‑stimulated with different doses (1,000, 500, 250 and 125 ng/ml) of rhMFG‑E8 or PBS for 2 h, and then plated in 500 µl volume at the
Boyden chamber inserts. The outer compartment of the inserts contained 500 µl of RPMI medium with 50 ng/ml of recombinant human interleukin‑8 (IL‑8) as
a chemoattractant. After 1.5 h of incubation, the upper surface of the filter was swabbed with cotton‑tipped applicators to remove non‑migratory cells. Migrated
cells were fixed with 4% paraformaldehyde (PFA) and stained with propidium iodide (PI) (1 µg/ml). A total of 6 random microscopic fields per well were
counted. Scale bar, 100 µm. (B) The average number of migrated dHL‑60 cells is plotted in a bar diagram where the results are expressed as the means ± SE
obtained from 6 fields/group of 3 independent experiments. *P<0.05 vs. PBS treatment.

rhMFG‑E8 downregulates CXCR2 surface expression by
upregulating intracellular GRK2 expression in dHL‑60 cells.
CXCR2, a surface receptor for the chemokine, IL‑8, plays a
crucial role in IL‑8‑dependent neutrophil migration (15,16,37).
The dHL‑60 cells stimulated with rhMFG‑E8 showed a
significant downregulation in CXCR2 expression at their
cell surface (Fig. 2A and B), which was further linked to the
decrease in neutrophil migration following stimulation with
rhMFG‑E8. Since intracellular GRK2 serves as a negative regulator of surface CXCR2 expression in neutrophils, we wished
to assess intracellular GRK2 expression in the dHL‑60 cells
following stimulation with rhMFG‑E8. Of note, we observed
a significant upregulation in intracellular GRK2 expression
in the dHL‑60 cells stimulated with rhMFG‑E8, as revealed

by flow cytometric analysis (Fig. 2C and D). Consistently,
western blot analysis of GRK2 protein expression also revealed
the reproducible findings of its upregulation upon rhMFG‑E8
stimulation in a time‑dependent manner (Fig. 2E), suggesting
that the inhibition of CXCR2 expression in dHL‑60 cells may
be mediated through the upregulation of GRK2 expression.
rhMFG‑E8 upregulates MAP kinase phosphorylation through
αv β3‑integrin. To determine whether rhMFG‑E8 alters MAP
kinase phosphorylation, the dHL‑60 cells were treated
with rhMFG‑E8 for different periods of time and we then
measured the p38 and ERK phosphorylation levels by western
blot analysis. As shown in Fig. 3A and B, the dHL‑60 cells
stimulated with rhMFG‑E8 showed a significant upregulation
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Figure 2. Expression of CXCR2 and G protein‑coupled receptor kinase 2 (GRK2) in recombinant human milk fat globule‑epidermal growth factor‑factor 8
(rhMFG‑E8)‑treated neutrophils. (A) Differentiated HL‑60 (dHL-60) cells (1.5x106 cells) treated with rhMFG‑E8 (500 ng/ml) for 2 h were surface-stained
with PE‑CXCR2 and then subjected to flow cytometric analysis. Data were analyzed by Flowjo software with 15,000 events per sample. Isotype controls and
Fc receptor blocker were used for all the samples. The representative histograms for PBS and rhMFG‑E8‑treated dHL‑60 cells obtained from 3 independent
experiments are shown. (B) Bar diagram representing the mean fluorescence intensities (MFI) of the PBS- and rhMFG‑E8‑treated samples are shown. Data are
expressed as the means ± SE (n=3 samples/group), obtained from 3 independent experiments. *P<0.05 vs. PBS treatment. (C and D) To examine the expression
of intracellular GRK2 levels, dHL‑60 cells (5x106 cells) treated with rhMFG‑E8 (500 ng/ml) for 2 h were first surface-stained with PE‑CXCR2, and then to
examine intracellular GRK2 expression, cells were fixed and permeabilized with Intraprep, followed by staining with FITC‑GRK2 antibodies. After washing,
the stained cells were subjected to flow cytometry using a FACSVerse flow cytometer. Appropriate isotype controls and Fc receptor blocker were used for all
the samples. Representative histogram and the bar diagrams indicating the MFI of PBS and rhMFG‑E8‑treated samples are shown. Data are expressed as the
means ± SE (n=3 samples/group), obtained from 3 independent experiments. *P<0.05 vs. PBS treatment. (E) Differentiated HL‑60 cells (1.5x106/ml) were placed
into 1.5 ml microfuge tubes with Opti‑MEM and then stimulated with either rhMFG‑E8 (500 ng/ml) or PBS for different periods of time. Following incubation,
the cell lysates were harvested and then subjected to western blot analysis using rabbit anti‑GRK2 monoclonal antibody. Results were normalized to β‑actin as
an internal control and are expressed as the fold induction in comparison to the 0 min time point. Data are expressed as the means ± SE (n=3 samples/group),
obtained from 3 independent experiments. *P<0.05 vs. 0 min.

in p38 and ERK phosphorylation in a time‑dependent manner
with the highest induction in their phosphorylation observed at

the 20- and 30-min time points; after these time points, their
phosphorylation decreased to basal levels. Since αvβ3‑integrin
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antibody for αv‑integrin or IgG isotype antibody followed
by stimulation with rhMFG‑E8, which evidently revealed
that the promoting effects of rhMFG‑E8 on p38 and ERK
phosphorylation were notably diminished (Fig. 3C), indicating
the role of αvβ3‑integrin in transducing MFG‑E8‑mediated
downstream signaling and MAP kinase activation.
rhMFG‑E8 modulates CXCR2 and GRK2 expression through
αv β3‑integrin. To determine the involvement of αvβ3‑integrin
in the rhMFG‑E8‑mediated alteration in CXCR2 and
GRK2 expression, the dHL‑60 cells were pre‑treated with
anti‑αv‑integrin antibody to block the MFG‑E8 receptor for the
transmission of downstream signaling. As shown in Fig. 4A,
pre‑treatment of the cells with anti‑αv‑integrin antibody neutralized the rhMFG‑E8-induced downregulation in the surface
expression of CXCR2, while a significant downregulation in
CXCR2 surface expression was observed in the cells treated with
the IgG isotype control. Similarly, the expression of GRK2 was
induced in the rhMFG‑E8‑stimulated dHL‑60 cells pre‑treated
with the IgG isotype control; conversely the rhMFG‑E8-induced upregulation in GRK2 expression was diminished in the
cells pre‑treated with anti‑αv‑integrin (Fig. 4B). Taken together,
these data clearly indicate that the MFG‑E8‑mediated downregulation of CXCR2 and the upregulation of GRK2 expression
are transmitted through the αvβ3‑integrin pathway.

Figure 3. Recombinant human milk fat globule‑epidermal growth
factor‑factor 8 (rhMFG‑E8) activates mitogen‑activated protein (MAP) kinases
through αvβ3‑integrin. (A and B) Differentiated HL‑60 cells (1.5x106/ml) were
placed into 1.5 ml microfuge tubes with Opti‑MEM and then stimulated with
rhMFG‑E8 (500 ng/ml) for different periods of time. Following incubation, the
cell lysates were harvested and subjected to western blot analysis using monoclonal antibodies for phospho and total p38 and ERK. Results are normalized
with total p38 and ERK as loading control and are expressed as the fold induction
in comparison to the 0 min time point. Data are expressed as the means ± SE (n=3
samples/group), obtained from 3 independent experiments.*P<0.05 vs. 0 min.
(C) A total of 1.5x106 dHL‑60 cells was placed into 1.5 ml microfuge tubes
containing 1 ml of Opti‑MEM. The cells were then pre‑treated with 1 µg/ml
of each of the IgG isotype control or anti‑αv‑integrin neutralizing antibody for
1 h at 37˚C. The cells were then stimulated with rhMFG‑E8 (500 ng/ml) or
PBS for 30 min and then subjected to western blot analysis using antibodies for
p‑p38, and ERK, and total p38 and ERK. Representative blots obtained from
3 independent experiments are shown. *P<0.05 vs. 0 min.

recognizes MFG‑E8, we wished to determine whether this
integrin is involved in the MFG‑E8‑mediated signal transduction
of p38 and ERK phosphorylation in the dHL‑60 cells. For this
purpose, we first treated the dHL‑60 cells with the neutralizing

MAP kinase inhibitors neutralize the rhMFG‑E8-induced
inhibition of CXCR2 and enhancement of GRK2 expression.
To determine the role of MAP kinases in the rhMFG‑E8‑mediated inhibition of CXCR2 expression, the dHL‑60 cells
were pre‑treated with MAP kinase inhibitors and the effects
of rhMFG‑E8 on CXCR2 expression were then evaluated. As
shown in Fig. 5A, pre‑treatment of the cells with the specific
inhibitors of p38 and ERK diminished the negative regulatory
effects of rhMFG‑E8 on CXCR2 which led to the downregulation of its surface expression, indicating the involvement of
MAP kinases in rhMFG‑E8‑mediated signaling. Similarly, the
rhMFG‑E8-induced upregulation of GRK2 was also diminished
when the p38 and ERK molecules were blocked by using their
specific inhibitors as compared to the DMSO control (Fig. 5B).
These data clearly indicate that the rhMFG‑E8‑mediated downstream signaling which downregulates CXCR2 and upregulates
GRK2 is mediated through MAP kinase activation.
Inhibition of αv‑integrin and MAP kinases diminishes the
rhMFG‑E8‑mediated downregulation in neutrophil migra‑
tion. In order to determine the involvement of αvβ3‑integrin
and MAP kinases in the rhMFG‑E8‑mediated inhibition of
neutrophil migration, the dHL‑60 cells were pre‑treated with
anti‑αv‑integrin antibody and the MAP kinase inhibitors, and
the effects of rhMFG‑E8 on neutrophil migration were antibody
evaluated. As shown in Fig. 6A and B, pre‑treatment of the cells
with anti‑αv‑integrin antibody and MAP kinase inhibitors markedly reversed the inhibitory effects of rhMFG‑E8 on neutrophil
migration. Collectively, these findings clearly indicate that
MFG‑E8 inhibits neutrophil migration by downregulating
surface CXCR2 expression through the upregulation of the
expression of the intracellular negative regulator, GRK2, and
this event is mediated by αvβ3‑integrin‑mediated MAP kinase
activation (Fig. 6C).
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Figure 4. Recombinant human milk fat globule‑epidermal growth
factor‑factor 8 (rhMFG‑E8) regulates CXCR2 and G protein‑coupled receptor
kinase 2 (GRK2) expression through αvβ3‑integrin. (A) Differentiated HL‑60
(dHL-60) cells (1.5x106) were placed into 1.5 ml microfuge tubes containing
1 ml of Opti‑MEM. The cells were pre‑treated with 1 µg/ml of each of the IgG
isotype control or anti‑αv‑integrin neutralizing antibody for 1 h at 37˚C. The
cells were then stimulated with rhMFG‑E8 (500 ng/ml) or PBS for 2 h and then
subjected to flow cytometry using PE‑labeled anti‑CXCR2 antibody. The mean
fluorescence intensities (MFI) of the isotype- and anti‑αv‑integrin‑treated
samples are shown. Data are expressed as the means ± SE (n=3 samples/group),
obtained from 3 independent experiments. *P<0.05 vs. PBS treatment. (B) A
total of 1.5x106 dHL‑60 cells was placed into 1.5 ml microfuge tubes containing 1 ml of Opti‑MEM. The cells were then pre‑treated with 1 µg/ml of
each of the IgG isotype control or anti‑αv‑integrin neutralizing antibody for 1 h
at 37˚C. The cells were then stimulated with rhMFG‑E8 (500 ng/ml) or PBS for
2 h and then subjected to western blot analysis using anti‑GRK2 antibody. The
blot was stripped off and re‑probed for anti‑β‑actin antibody, which served as
the loading control. Representative blots and corresponding densitometric bar
diagram obtained from 2 independent experiments are shown.

Discussion
Neutrophils are the first line of defense against tissue infection, trauma, stress insults and injury. These cells play a key
role in the defense against bacterial, fungal and viral infections
and a growing body of evidence suggests that neutrophils may
also represent a critical link between the innate and adaptive
immune system (1). Therefore, the migration of neutrophils
to infected tissue and secondary lymphoid organs is critical
for effective immune responses to the majority of pathogens;
however, uncontrolled migration can lead to tissue damage
and chronic inflammation (2). In our previous studies, we
reported an enhanced infiltration of neutrophils into the

Figure 5. Recombinant human milk fat globule‑epidermal growth
factor‑factor 8 (rhMFG‑E8) regulates CXCR2 and G protein‑coupled
receptor kinase 2 (GRK2) expression through the p38 and ERK pathways.
(A) Differentiated HL‑60 (dHL-60) cells were placed into 1.5 ml microfuge
tubes at a density of 1.5x10 6 cells/ml of Opti‑MEM. The cells were then
pre‑treated with the p38 inhibitor, SB203580, of the ERK inhibitor, PD98059,
at a concentration of 10 µM of each for 1 h at 37˚C. Following incubation,
the cells were then stimulated with rhMFG‑E8 (500 ng/ml) or PBS for 2 h
followed by the assessment of CXCR2 by flow cytometry. Mean fluorescence
intensities (MFI) obtained from 3 independent experiments are plotted
into the bar diagram.*P<0.05 vs. PBS treatment. (B) Western blot analysis
using anti‑GRK2 antibody. The blot was stripped off and re‑probed for
anti‑β ‑actin antibody, which served as the loading control. Representative
blots obtained from 2 independent experiments are shown. Densitometric
data are expressed as the means ± SE (n=2 samples/group), obtained from
2 independent experiments.

vital organs following sepsis, ALI, renal, and gut I/R injury,
causing severe inflammation and tissue damage. However, the
deleterious events caused by excessive neutrophil accumulation
were ameliorated by exogenous treatment with recombinant
MFG‑E8 which attenuated neutrophil migration and infiltration into tissues (8,9,38).
Although we have initially elucidated the involvement of the
the downregulation of the IL‑8 receptor, CXCR2, at the neutrophil cell surface due to the upregulation of its intracellular
negative regulator, GRK2, in rmMFG‑E8‑treated murine bone
marrow-derived neutrophils (8), in this study, in order to reveal
the mechanisms through which MFG‑E8 attenuates neurophil
migration, we utilized the human neutrophil cell line, HL‑60,
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Figure 6. Treatment with anti‑αv‑integrin antibody and mitogen‑activated protein (MAP) kinase inhibitors counteracts recombinant human milk fat globule‑epidermal growth factor-factor 8 (rhMFG‑E8)‑mediated downregulation of neutrophil migration. (A) Differentiated HL‑60 (dHL-60) cells (3x105) were pre‑stimulated
with 1 µg/ml of each of the IgG isotype control, anti‑αv‑integrin neutralizing antibody, the p38 inhibitor, SB203580 (SB), of the ERK inhibitor, PD98059 (PD), at a
concentration of 10 µM for 1 h at 37˚C in their respective 1.5 ml microfuge tubes. The cells were then stimulated with rhMFG‑E8 (500 ng/ml) or PBS for 2 h, and
then plated in 500 µl volume in the Boyden chamber inserts. The outer compartment of the inserts contained 500 µl of RPMI medium with 50 ng/ml of recombinant
human interleukin‑8 (IL‑8) as a chemoattractant. After 1.5 h of incubation, the upper surface of the filter was swabbed with cotton‑tipped applicators to remove
non‑migratory cells. Migrated cells were fixed with 4% paraformaldehyde (PFA) and stained with propidium iodide (PI) (1 µg/ml). A total of 6 random microscopic
fields per well were counted. Scale bar, 100 µm. (B) The average number of migrated dHL‑60 cells are plotted in a bar diagram where the results are expressed
as the means ± SE obtained from 6 fields/group of 3 independent experiments. *P<0.05 vs. PBS. (C) Mechanistic finding. The secretory glycoprotein, MFG‑E8
binds to its receptor, αvβ3‑integrin, and transduces downstream signaling of MAP kinase (p38 and ERK) activation. The activated MAP kinases then upregulate
G protein‑coupled receptor kinase 2 (GRK2) which in turn negatively regulates the surface exposure of CXCR2, thereby attenuating neutrophil migration.

and stimulated the cells with rhMFG‑E8 and focused on evaluating the upstream signaling components which may result in

the modulation of GRK2/CXCR2 signaling. We observed a
marked induction in the levels of p‑p38 and ERK MAP kinases
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following stimulation of the HL‑60 cells with rhMFG‑E8. To
confirm this novel link between MFG‑E8 and MAP kinases,
we utilized a two‑step blocking strategy: i) neutralization of
the αvβ3‑integrin heterodimer by the anti‑αv‑integrin antibody
abrogated the rhMFG‑E8-induced increase in the levels of MAP
kinases; and ii) inhibition of MAP kinases by their inhibitors
diminished the inhibitory effects of rhMFG‑E8 on neutrophil
migration through the modulation of GRK2/CXCR2, thus
suggesting the involvment of these two novel pathways in
the MFG‑E8‑mediated downregulation of human neutrophil
migration.
MFG‑E8 has two functional domains: the N‑terminal EGF
domain that bind to αvβ3‑integrin of most hematopoietic cells,
and the C‑terminal discoidin domains that recognizes the PS in
apoptotic cells (26). In this study, we considered αvβ3‑integrin
as the gateway for MFG‑E8‑mediated signal transduction.
Structurally, αvβ3‑integrin is a heterodimeric transmembrane
receptor formed by the non‑covalent association of the α and
β subunits (39). In this study, we demonstrated that the
blocking αv‑integrin in neutrophils effectively diminished the
effects of rmMFG‑E8 on IL‑8‑mediated HL‑60 cell migration
through the activation of MAP kinases and the modulation
of GRK2/CXCR2 expression, indicating the involvement of
αv‑integrin in mediating MFG‑E8 activity. Similar to our
results demonstrating that the blocking of αv‑integrin abrogates MFG‑E8 signaling, Cheyuo et al also adopted the same
approach to block only αv‑integrin for the functional assessment
of MFG‑E8‑mediated anti‑inflammatory and anti‑apoptotic
roles in cerebral ischemic injury (40). Furthermore, our findings identify the integrin signaling pathway as another critical
factor in controlling GRK2‑mediated CXCR2 downregulation.
It is already known that MFG‑E8 was first discovered as
a scavenging factor to promote the phagocytosis of apoptotic
cells by macrophages through the formation of a bridge between
them (26). However, MFG‑E8 has several immunological and
physiological functions. Apart from participating in the phagocytic clearance of apoptotic cells, MFG‑E8 directly attenuates
pro‑inflammatory milieu by inhibiting nuclear factor (NF)‑κB
in in vivo and in vitro systems (31,41). In addition, MFG‑E8 has
recently been reported to have growth-promoting functions,
where it promotes intestinal epithelial cell regeneration through
the PKCε‑mediated pathway (42). Furthermore, MFG‑E8 is
also known to promote AKT and Twist‑dependent malignant
melanoma progression (43) and ERK‑mediated sperm‑egg
interaction (44), indicating its roles in manipulating intracellular
signaling required for cell proliferation and their interaction
with each other. Although the involvement of MAP kinases
in controlling neutrophil migration has been well elucidated,
to the best of our knowledge, there is no published study to
date utilizing MFG‑E8 for the activation of MAP kinases,
which are linked to neutrophil migration. In this study,
indicative of its role in immune cell migration, we observed
a decrease in neutrophil migration as a result of the increased
phosphorylation of p38 and ERK MAP kinases, which led to
the downregulation of CXCR2 surface expression through the
GRK2‑dependent pathway. However, a recent study suggested
that the different components of MAP kinases have distinct
regulatory roles in neutrophil migration (25); the authors
revealed the ‘stop’ and ‘go’ signal in the context of regulating
neutrophil migration utilizing ERK and p38 phosphorylation,

respectively. Based on their findings, the activation of p38
promoted, whereas the phosphorylation of ERK inhibited
neutrophil migration. In accordance with their findings, in this
study, using rhMFG‑E8, we also found similar results in the
context of the upregulation of ERK phosphorylation which
may inhibit neutrophil migration. However, the difference
between their study and ours is that in our study, rhMFG‑E8
mediated the upregulation of p38 phosphorylation, inhibiting
neutrophil migration, while in their study, p38 phosphorylation promoted neutrophil migration. However, in our study we
tried to exclude this divergence by utilizing the p38 inhibitor,
SB203580, which diminished the rhMFG‑E8-induced downregulation of neutrophil migration, hence suggesting a negative
regulatory role of p38 in IL‑8‑mediated neutrophil migration
upon stimulation with rhMFG‑E8. The study carried out by
Liu et al is to some extent different from our study in that they
utilized fMLP as a chemoattractant and revealed the regulatory
mechanism of neutrophil migration by treating dHL‑60 cells
directly with fMLP, and although the phosphorylation of p38
and ERK was induced, the feedback inhibition was initiated
only by phospho‑ERK (25). The involvement of MAP kinases
in neutrophil migration can also be explained by another study
in which pre‑treatment of neutrophils with TLR ligands attenuated neutrophil migration due to high GRK2 expression (45).
Since TLR ligations to their ligands induces the activation of
MAP kinases, it is therefore conceivable that due to the activation of MAP kinases, the migration of neutrophils may be
attenuated, which is in agreement with our findings that the
MFG‑E8‑mediated upregulation of MAP kinase phosphorylation attenuated neutrophil migration. MFG‑E8 contains EGF
domains at its N‑terminal domain. Since several proteins
which have an EGF domain in their backbone, e.g., EGF,
heparin‑binding EGF‑like growth factor (HB‑EGF), Notch,
and growth arrest‑specific 6 (Gas6) are known to upregulate
MAP kinases to execute their relevant functions (46‑49), the
upregulation of MAP kinase phosphorylation by rhMFG‑E8
may be comparable.
Developmental endothelial locus‑1 (Del‑1), a probable paralogue protein of MFG‑E8, which has a sequence and domain
structure similar to MFG‑E8, also shows identical biochemical
functions of divalent binding activity to cell membrane
molecules, such as MFG‑E8 (50,51). The RGD motif in the
second EGF‑like domain is conserved between MFG‑E8 and
Del‑1, both of which show binding to cells expressing αvβ3 and
αvβ5 integrins. A recent study utilizing Del‑1 indicated a significant inhibition of neutrophil migration through the blocking of
the interaction of leukocyte functional antigen‑1 (LFA‑1) iin
neutrophils and intercellular adhesion molecule-1 (ICAM‑1) in
endothelial cells, hence inhibiting neutrophil migration (52). In
this study, we revealed a mechanism involving MAP kinases and
the GRK2‑mediated downregulation of CXCR2 by stimulation
with MFG‑E8 for the inhibition of neutrophil migration; this
provides a novel direction for the modulation of the intracellular
signaling cascade. Since MFG‑E8 and Del‑1 are homologous,
the findings regarding Del‑1 may be implemented so as to
reveal the complete mechanisms through which MFG‑E8
attenuates neutrophil migration. In this regard, since MFG‑E8
has RGD in its backbone, emphasis therefore be placed on
whether MFG‑E8 blocks the interaction of extracellular matrix
proteins to their integrin receptor to attenuate their binding for
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the initial attachment of neutrophils to endothelial cells as the
first step of neutrophil migration. Therefore, deducing the role
of MFG‑E8 to the steps of roling and adherence may prove to
be of considerable interest.
In conclusion, in this study, we identified a novel link
between MAP kinases and GRK2, playing a negative regulatory role on CXCR2 surface expression (Fig. 6C). Our data
may lead to translational studies being carried out for the
identification of potential drug candidates which can modulate neutrophil migration, leading to the remission of several
inflammatory diseases in which controlling exaggerated
neutrophil infiltration is a major challenge.
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